FURLONG study: reply on the patient reported outcome measures and thresholds

We came across the publication entitled "Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer". 1 We would like to commend the authors for incorporating patient reported outcomes (PROs) in the evaluation of the treatment efficacy of furmonertinib.PROs and health-related quality of life assessments play an important role in the comprehensive evaluation of the impact of cancer treatments on the patient-reported experience, which will ultimately provide better informed shared-decision making between clinicians and their patients, and across different stakeholders.However, we would like to address one issue that was discussed in the study's limitations.The authors suggest that the EORTC Quality of Life Questionnaires, QLQ-C30 and QLQ-LC13, lack flexibility and fail to